CHICAGO--(BUSINESS WIRE)--GTCR, a leading private equity firm, announced that its portfolio company Cord Blood Registry (“CBR” or the “Company”) has signed a definitive agreement to be acquired by AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG), a specialty pharmaceutical company that focuses on maternal health and hematology, for $700 million. The transaction is expected to close in the third quarter upon the receipt of regulatory approvals and satisfaction of other customary conditions. Founded in 1
| < Prev | Next > |
|---|
